Quick Links
Privacy Policy
Terms & Conditions
Executive Board
Faculty Portal
Google +
Regus World Trade Centre
Muelle de Barcelona, edif. Sur, 2ª Planta
Barcelona Cataluña
08039 Spain
P: 1-609-378-3701

Copyright © 2018
Physicians’ Education Resource ®, LLC.
All rights reserved.

3rd Annual European Symposium on Lung Cancers™

3rd Annual European Symposium on Lung Cancers™

11, May 2019
Barcelona, Spain

Hilton Barcelona
Avenida Diagonal, 589-591
08014 Barcelona, Spain
Tel: +34 934 95 77 77


We are pleased to announce the 3rd Annual European Symposium on Lung Cancers™, which will focus on how clinicians can best incorporate new approaches, including personalized medicine, targeted agents, and immunotherapy. While these new approaches hold the promise of improved outcomes for patients with lung cancer, they also lead to increased demand on physicians to understand new paradigms in molecular testing, treatment selection, and management of adverse events with new categories of therapies.

This highly interactive and practical program will include internationally recognized experts in lung cancer describing recent key studies in the field, as well as extensive case-based discussions that go beyond the data in addressing challenges faced in the clinic. This meeting will also enable participants to engage directly with experts and with their peers to share their perspectives, personal experiences, and approaches to optimizing care for their patients with lung cancer.

2018 Featured Topics

  • State-of-the-art application of immunotherapy in metastatic non-small cell lung cancer (NSCLC)
  • Emergence of immunotherapy in locally advanced NSCLC
  • New standards for patients with EGFR-mutated and ALK-rearranged NSCLC, and recent data on therapies to target other oncogenic drivers
  • Role of liquid biopsies for treatment selection
  • Pulmonologist’s perspective on best practices in lung cancer diagnosis and therapy
  • Therapeutic advances in small cell lung cancer (SCLC) and mesothelioma

Target Audience

This educational activity is directed toward medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, as well as other healthcare professionals involved in the treatment and management of patients with lung cancer.

Learning Objectives

At the conclusion of this symposium, you should be better prepared to:

  • Assess methods by which prognostic and predictive tumor characteristics can be identified in advanced forms of lung cancer
  • Utilize tumor and patient characteristics to optimize personalized treatment sequencing for patients with advanced NSCLC
  • Discuss current and emerging roles for single agent and combination immunotherapeutic strategies in the management of advanced lung cancers
  • Apply personalized approaches to manage EGFR-mutated advanced NSCLC by assessment of mutation subtypes in multiple lines of care
  • Assess evolving data sets concerning the use of ALK inhibition in front-line and subsequent lines of care in advanced NSCLC
  • Discuss emerging targeted approaches for oncogenic drivers in NSCLC beyond EGFR and ALK
  • Identify approaches to address treatment-related toxicities in patients with lung cancer
  • Integrate personalized approaches to manage challenging cases in advanced lung cancer settings

Become a Member

Forgot Password?
Filter By